Literature DB >> 29266445

Evaluation of the circulating MicroRNA-495 and Stat3 as prognostic and predictive biomarkers for lower extremity deep venous thrombosis.

Nai-Xuan Li1, Jing-Wu Sun2, La-Mei Yu3.   

Abstract

This study aims to elucidate the prognostic and predictive biomarker of miR-495 and Stat3 in peripheral blood in relation to lower extremity deep venous thrombosis (DVT). Patients with lower limb fractures were assigned into case and control groups. Rats were allocated into blank (normal rats), sham (normal rats), DVT, miR-495 mimic, miR-495 inhibitor, over-Stat3, and si-Stat3 groups. ELISA was used to detect levels of prothrombin time (PT), endothelin-1 (ET-1), Human Fibrinogen (FIB), D-Dimer, blood coagulation factors V and VIII, tissue type plasminogen activator (t-PA), platelet activating factor (PAF), protein C and Stat3. qRT-PCR was employed for the evaluation of the expressions of miR-495 and Stat3, while receiver operating characteristic (ROC) curve was constructed to assess the predictive value of miR-495 and Stat3 as well as the treatment outcomes of patients with lower limb fractures. Logistic regression analyses were conducted in order to correlate indexes and lower extremity DVT. miR-495 overexpression, t-PA, PAF, and protein C were confirmed to be protective factors, while Stat3 overexpression, PT, ET-1, FIB, D-Dimer, blood coagulation factor V, and VIII were all ultimately considered to be risk factors of lower extremity DVT. Stat3 was confirmed to be the target gene of miR-495. Compared with the blank group, the length and weight of the thrombus as well as the ratio between length and weight, mRNA and protein expression of Stat3 were reduced in the miR-495 mimic and si-Stat3 groups. Our findings suggest that through the suppression of Stat3 expression, miR-495 prohibits lower extremity DVT in peripheral blood.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  MicroRNA-495; Stat3; lower limb fracture; perioperative deep vein thrombosis; peripheral blood; target gene

Mesh:

Substances:

Year:  2018        PMID: 29266445     DOI: 10.1002/jcb.26633

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Silica nanoparticles trigger the vascular endothelial dysfunction and prethrombotic state via miR-451 directly regulating the IL6R signaling pathway.

Authors:  Lin Feng; Xiaozhe Yang; Shuang Liang; Qing Xu; Mark R Miller; Junchao Duan; Zhiwei Sun
Journal:  Part Fibre Toxicol       Date:  2019-04-11       Impact factor: 9.400

2.  MicroRNA-495 serves as a diagnostic biomarker in patients with sepsis and regulates sepsis-induced inflammation and cardiac dysfunction.

Authors:  Hailei Guo; Liying Tang; Jianjun Xu; Cai Lin; Xiangwei Ling; Caijiao Lu; Zhengjun Liu
Journal:  Eur J Med Res       Date:  2019-11-26       Impact factor: 2.175

3.  Downregulation of interleukin-6 and C-reactive protein underlies a novel inhibitory role of microRNA-136-5p in acute lower extremity deep vein thrombosis.

Authors:  Minghui Ou; Shaobo Hao; Jing Chen; Shibo Zhao; Shichao Cui; Jie Tu
Journal:  Aging (Albany NY)       Date:  2020-11-14       Impact factor: 5.682

Review 4.  Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.

Authors:  Masashi Ishikawa; Masae Iwasaki; Atsuhiro Sakamoto; Daqing Ma
Journal:  BMC Anesthesiol       Date:  2021-03-09       Impact factor: 2.217

5.  Effect of miR-495 on lower extremity deep vein thrombosis through the TLR4 signaling pathway by regulation of IL1R1.

Authors:  Ke-Cheng Tang; Zhi-Peng Yang; Qiu Zeng; Jing Wang; Feng Guo; Yu Zhao
Journal:  Biosci Rep       Date:  2018-12-21       Impact factor: 3.976

6.  Nomogram for Predicting Deep Venous Thrombosis in Lower Extremity Fractures.

Authors:  Ze Lin; Bobin Mi; Xuehan Liu; Adriana C Panayi; Yuan Xiong; Hang Xue; Wu Zhou; Faqi Cao; Jing Liu; Liangcong Hu; Yiqiang Hu; Lang Chen; Chenchen Yan; Xudong Xie; Junfei Guo; Zhiyong Hou; Yun Sun; Yingze Zhang; Yu Hu; Guohui Liu
Journal:  Biomed Res Int       Date:  2021-06-22       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.